Wyeth will buy $10 million in ViroPharma shares after the two collaborators achieved proof-of-concept stage for an experimental hepatitis C therapy. Preliminary data from Phase I should be available by the end of August. Report [1]
Links:
[1] http://philadelphia.bizjournals.com/philadelphia/stories/2006/08/14/daily1.html?jst=b_ln_hl